Anticentromere antibodies in subjects with no apparent connective tissue disease

Shu-Ling Lee, Gregory J Tsay, Rong-Tai Tsai

Abstract

Objectives—To study the association of anticentromere antibodies (ACA) in various diseases.

Methods—A total of 4800 consecutive serum samples were tested for ACA by indirect immunofluorescence using HEp-2 cells as substrates and by immunoblotting of Molt-4 cell mitotic chromosomal antigens and recombinant CENP-B protein.

Results—Anticentromere antibodies were identified in the serum samples of 24 subjects, including eight without apparent connective tissue diseases, six with primary biliary cirrhosis, two with diffuse scleroderma, one with pulmonary hypertension, one with primary Raynaud’s phenomenon, one with CREST syndrome (calcinosis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia), and five with other connective tissue diseases. By immunoblotting using Molt-4 cells mitotic chromosomal antigens three centromere antigens were recognised by these serum samples. These were: CENP-A (17 kilodalton recognised by 22 of 24 ACA positive serum samples); CENP-B (80 kilodalton recognised by 22 of 24 ACA positive serum samples); and CENP-C (140 kilodalton recognised by 19 of 24 ACA positive serum samples). There was no specific pattern for serum samples from patients with different groups of diseases on immunoblotting. Recombinant CENP-B proteins were all recognised by these samples. Patients without apparent connective tissue disease often had a lower ACA titre than patients with primary biliary cirrhosis.

Conclusions—These data suggest that a positive result for ACA does not always indicate the presence of a connective tissue disease.

Subjects and methods

Patients

The serum samples used for this study were from 24 patients positive for ACA as determined by indirect immunofluorescence. These serum samples were found among 4800 samples submitted during four years of antinuclear antibody testing. Patients were followed up at Chung Shan Medical and Dental College Hospital and in local clinics around Taichung, Taiwan. All patients positive for ACA were examined by a member of the rheumatology faculty at the hospital and patients taking drugs such as d-penicillamine known to induce ACA were excluded.

The diagnosis of Raynaud’s phenomenon was based on a typical history and on plexomorphic patterns during cold provocation or warming, or both. Suspected secondary Raynaud’s phenomenon was diagnosed when a patient showed a few symptoms of a connective tissue disease but without all the criteria necessary for a definite diagnosis. The criteria for diagnosis of primary biliary cirrhosis were accepted clinical and histological criteria. Scleroderma was identified according to the preliminary criteria for the diagnosis of systemic sclerosis. Patients were grouped as having no apparent connective tissue disease when none of the signs nor symptoms of connective tissue diseases were present and laboratory tests for erythrocyte sedimentation rate, rheumatoid factor, C reactive protein, and blood count were normal. In all patients with ACA a careful history and physical examination were performed with special attention to signs and symptoms of connective tissue disease such as arthralgia, arthritis, Raynaud’s phenomenon, sclerodactyly, proximal scleroderma, telangiectasia, dysphagia, pulmonary symptoms, mouth ulcers, digital scars or loss of finger pad substance, and calcinosis, photosensitivity, and skin rash.

Anticentromere antibodies (ACA) have been described in a variety of presumed autoimmune diseases including CREST syndrome (calcinosis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia), diffuse systemic sclerosis, primary biliary cirrhosis, and other connective tissue diseases. It is generally accepted that there is a strong correlation between ACA and Raynaud’s phenomenon, and ACA often identify patients with less severe disease. In this study we investigated the clinical correlates of ACA and attempted to determine whether or not a special pattern of these chromosomal antigens recognised by serum samples from different groups of patients could be established by immunoblotting. We also evaluated the significance of titres of ACA in various diseases.

INDIRECT IMMUNOFLUORESCENCE

Anticentromere antibodies and antinuclear antibodies were detected by indirect
immunofluorescence using HEp-2 cells (Antibodies Inc, Davis, CA, USA) as described previously. Each serum sample was screened for the presence of ACA at a 1:80 dilution and further serial fourfold dilutions were performed if the sample was positive for ACA. Anticentromere antibodies were considered to be present in intercellular phases by typical discrete speckled staining and by characteristic localisation in mitotic cells. Immunoglobulin isotypes and the IgG subclass of ACA were also determined by indirect immunofluorescence with fluorescein conjugated goat antihuman IgG, IgM, and IgA (Behringwerke, Marburg, Germany) for immunoglobulin isotypes and fluorescein conjugated monoclonal antihuman IgG subclass (Sigma Chemical, St Louis, MO, USA) for IgG subclasses.

**Results**

Twenty-four serum samples were positive for ACA by indirect immunofluorescence on HEp-2 cells. Figure 1 gives the clinical diagnosis and titres of ACA of the 24 patients with positive results. There were three men and 21 women aged from 35 to 82 years with a mean (SD) age of 61·54 (11·51) years. Of the 24 patients positive for ACA eight had no apparent connective tissue disease, six had primary biliary cirrhosis, two had systemic sclerosis, one had CREST syndrome, one had primary Raynaud’s phenomenon, five had suspected secondary Raynaud’s phenomenon, and one had pulmonary hypertension. The titres of ACA were significantly higher in patients with primary biliary cirrhosis than in patients without apparent connective tissue disease (p<0·05).

The distribution of immunoglobulin isotypes of ACA in different groups of patients was studied. IgG was present in all patients with ACA. IgM and IgA were less often present in these serum samples. Not all patients with primary biliary cirrhosis had IgM. The IgG subclasses were largely restricted to IgG1 and IgG3. The IgG1 subclass was found in 12 of 24 serum samples positive for ACA. IgG3 was present in four of 24 serum samples positive for ACA. There was no IgG2 and IgG4 in serum samples positive for ACA.

The table gives the clinical diagnosis of the eight patients without signs and symptoms of connective tissue disease. Anticentromere antibodies were accidentally found in these patients. All patients had various long term medical disorders not relating to connective tissue diseases, which included chronic dermatitis, valvular heart disease, chronic headache, cataract, polycystic kidney,
gallstones, and one was the healthy mother of an infant with congenital heart block. It is of interest to note that serum from patient 7 was accidentally found to contain ACA because she gave birth to a daughter with congenital heart block. Their serum samples did not contain any other known antibodies including antibodies to Ro/SS-A, La/SS-B, and RNP by immunoblotting.

Using a Molt-4 whole nuclei sonicate as the source of antigen for immunoblotting, ACA binding to 17 kilodalton (CENP-A), 80 kilodalton (CENP-B), and 140 kilodalton (CENP-C) antigens were observed (fig 2). Lane 1 shows a normal control serum. Lanes 2–4 were serum samples with ACA from patients with suspected secondary Raynaud’s phenomenon. Lanes 5 and 6 were from patients with primary biliary cirrhosis with ACA which reacted with 50 and 70 kilodalton proteins of mitochondrial antigens in addition to CENP-A, CENP-B, and CENP-C. Most serum samples positive for ACA recognised CENP-A protein (92%), CENP-B protein (92%), and CENP-C protein (79%). All 24 serum samples positive for ACA also recognised recombinant CENP-B protein by immunoblotting (data not shown).

Discussion
In this study, 8/24 or 33% of patients with ACA did not have any symptoms or signs of connective tissue disease. The patients were accidentally identified by antinuclear antibody screening at the hospital. They had multiple systemic disorders and had not taken drugs such as d-penicillamine known to induce ACA. This is the first study showing the highest prevalence of ACA in patients without rheumatic diseases. In contrast, most studies have shown that ACA are present primarily in patients with CREST syndrome and are strongly correlated with Raynaud’s phenomenon. The evolution of these patients without apparent connective tissue disease with positive ACA is unknown. These patients usually have relatively lower titres of ACA. Low titres of ACA have been reported in first and second degree relatives of patients with CREST syndrome in the absence of Raynaud’s phenomenon. Wade et al also reported two of 49 patients with ACA not associated with any symptoms or signs of connective tissue disease. It is not known whether our patients will develop overt rheumatic disease in the future. At present we cannot explain the significance of the occurrence of ACA in this group of patients.

Anticentromere antibodies were detected in six of 24 (25%) patients with primary biliary cirrhosis in this study. This is consistent with reports by other workers who have noted ACA in patients with primary biliary cirrhosis. This antibody seems to be another important autoantibody in addition to antimitochondrial antibodies in patients with primary biliary cirrhosis. Patients with primary biliary cirrhosis have the highest titres of ACA which are restricted to IgG only (fig 1). All these patients with primary biliary cirrhosis had at least one feature of scleroderma. A high titre of ACA has been reported to be associated with thrombotic vascular disease.

We found that most ACA were of the IgG isotype and largely restricted to the IgG1 and IgG3 subclasses. These results are in good agreement with those of French and Bernstein. Several reports have shown that IgG1 and IgG3 are the predominant subclasses of antibodies to Sm, RNP, histone, SS-B/La, dsDNA, and ssDNA in patients with systemic lupus erythematosus, Sjögren’s syndrome, and drug induced autoimmunity. As IgG1 and IgG3 are linked to immune responses dependent on T cells, the predominant subclasses of IgG1 and IgG3 displayed by these autoantibodies and ACA may indicate that a common immunological feature of
Anticentromere antibodies and connective tissue disease

autoantigens or a common control mechanism underlies the regulation of autoantibody expression in these autoimmune diseases.

Three centromere autoantigens were recognised by our serum samples positive for ACA at a frequency similar to other reports. There was no specific pattern of centromere antigens distinguishing the patient groups on immunoblotting. Recombinant CENP-B protein was recognised by all serum samples positive for ACA. This is consistent with the report of Earnshaw et al that CENP-B is a major centromere autoantigen.

Our study confirms that ACA can be found in a variety of connective tissue diseases and also in patients without apparent connective tissue disease. In this group the titre of ACA tends to be lower.

This study was partly supported by grant NSC 81-0412-B-040-502 from National Science Council, Taiwan. Recombinant CENP-B protein was kindly supplied by Dr Kevin F Sullivan, The Scripps Research Institute, La Jolla, CA, USA.

Anticentromere antibodies in subjects with no apparent connective tissue disease.

S L Lee, G J Tsay and R T Tsai

Ann Rheum Dis 1993 52: 586-589
doi: 10.1136/ard.52.8.586

Updated information and services can be found at:
http://ard.bmj.com/content/52/8/586

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/